{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:02Z","timestamp":1793924822585,"version":"4.8.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"41","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The best management approach for renin\u2013angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73\u20130.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66\u20132.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66\u20131.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76\u20131.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60\u20132.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56\u20131.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69\u20132.38; low certainty).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf573","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:27:21Z","timestamp":1753183641000},"page":"6145-6156","source":"Crossref","is-referenced-by-count":3,"title":["Discontinuation of renin\u2013angiotensin system inhibitors before non-cardiac surgery: a meta-analysis"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6002-3883","authenticated-orcid":false,"given":"Joseph Y","family":"Bena Nnang","sequence":"first","affiliation":[{"name":"Research Division, Winners Foundation , Yaounde ,","place":["Cameroon"]},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I , Yaounde ,","place":["Cameroon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticha B T","family":"Tembi","sequence":"additional","affiliation":[{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University , Atlanta, GA 30322 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G J","family":"Fodop","sequence":"additional","affiliation":[{"name":"Research Division, Winners Foundation , Yaounde ,","place":["Cameroon"]},{"name":"School of Health and Medical Sciences, Catholic University , Kumbo ,","place":["Cameroon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel G K","family":"Mekontso","sequence":"additional","affiliation":[{"name":"New York City Health + Hospitals, South Brooklyn Health , NY 11235 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatius N","family":"Esene","sequence":"additional","affiliation":[{"name":"Research Division, Winners Foundation , Yaounde ,","place":["Cameroon"]},{"name":"Faculty of Health Sciences, University of Bamenda , Bambili ,","place":["Cameroon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2026110518541877300_ehaf573-B1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2125.2000.00145.x","article-title":"Polypharmacy in a general surgical unit and consequences of drug withdrawal","volume":"49","author":"Kennedy","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2026110518541877300_ehaf573-B2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12871-018-0487-7","article-title":"Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis","volume":"18","author":"Ling","year":"2018","journal-title":"BMC Anesthesiol"},{"key":"2026110518541877300_ehaf573-B3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.12788\/jhm.3036","article-title":"Prospective randomized evaluation of preoperative angiotensin-converting enzyme inhibition (PREOP-ACEI)","volume":"13","author":"Shiffermiller","year":"2018","journal-title":"J Hosp Med"},{"key":"2026110518541877300_ehaf573-B4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1213\/ANE.0000000000002837","article-title":"A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery","volume":"127","author":"Hollmann","year":"2018","journal-title":"Anesth Analg"},{"key":"2026110518541877300_ehaf573-B5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/eurheartj\/ehad716","article-title":"Discontinuation vs. continuation of renin\u2013angiotensin system inhibition before non-cardiac surgery: the SPACE trial","volume":"45","author":"Ackland","year":"2024","journal-title":"Eur Heart J"},{"key":"2026110518541877300_ehaf573-B6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jama.2024.17123","article-title":"Continuation vs discontinuation of renin\u2013angiotensin system inhibitors before major noncardiac surgery: the stop-or-not randomized clinical trial","volume":"332","author":"Legrand","year":"2024","journal-title":"JAMA"},{"key":"2026110518541877300_ehaf573-B7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/M22-3157","article-title":"Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: an international randomized controlled trial","volume":"176","author":"Marcucci","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026110518541877300_ehaf573-B8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1213\/ANE.0b013e318241f6af","article-title":"Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery","volume":"114","author":"Turan","year":"2012","journal-title":"Anesth Analg"},{"key":"2026110518541877300_ehaf573-B9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2024.06.013","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"84","author":"Thompson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026110518541877300_ehaf573-B10","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026110518541877300_ehaf573-B11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1213\/ANE.0000000000000076","article-title":"The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients","volume":"118","author":"Twersky","year":"2014","journal-title":"Anesth Analg"},{"key":"2026110518541877300_ehaf573-B12","author":"Higgins"},{"key":"2026110518541877300_ehaf573-B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026110518541877300_ehaf573-B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00000542-199408000-00006","article-title":"Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction","volume":"81","author":"Coriat","year":"1994","journal-title":"Anesthesiology"},{"key":"2026110518541877300_ehaf573-B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00000539-200101000-00006","article-title":"Should the angiotensin II antagonists be discontinued before surgery?","volume":"92","author":"Bertrand","year":"2001","journal-title":"Anesth Analg"},{"key":"2026110518541877300_ehaf573-B16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026110518541877300_ehaf573-B17","author":"Review Manager (RevMan)"},{"key":"2026110518541877300_ehaf573-B18","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis","volume":"32","author":"Shi","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"2026110518541877300_ehaf573-B19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2026110518541877300_ehaf573-B20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026110518541877300_ehaf573-B21","author":"Higgins"},{"key":"2026110518541877300_ehaf573-B22"},{"key":"2026110518541877300_ehaf573-B23","author":"Sch\u00fcnemann"},{"key":"2026110518541877300_ehaf573-B24","author":"Sch\u00fcnemann"},{"key":"2026110518541877300_ehaf573-B25","author":"Sch\u00fcnemann"},{"key":"2026110518541877300_ehaf573-B26","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026110518541877300_ehaf573-B27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials","volume":"21","author":"Baujat","year":"2002","journal-title":"Stat Med"},{"key":"2026110518541877300_ehaf573-B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"2026110518541877300_ehaf573-B29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/HYPERTENSIONAHA.107.094235","article-title":"Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension","volume":"50","author":"Hermida","year":"2007","journal-title":"Hypertension"},{"key":"2026110518541877300_ehaf573-B30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2165\/00003088-198814040-00002","article-title":"Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases","volume":"14","author":"Duchin","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"2026110518541877300_ehaf573-B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1524-6175.2005.04556.x","article-title":"Angiotensin-converting enzyme inhibitors\u2019 side effects\u2014physiologic and non-physiologic considerations","volume":"7","author":"Sica","year":"2005","journal-title":"J Clin Hypertens"},{"key":"2026110518541877300_ehaf573-B32","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/41\/6145\/64160168\/ehaf573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/41\/6145\/64160168\/ehaf573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:21Z","timestamp":1793922861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/41\/6145\/8243848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":32,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2026,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf573","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,1]]},"published":{"date-parts":[[2025,8,29]]}}}